4 reports of this reaction
8.9% of all ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY reports
#1 most reported adverse reaction
MOVEMENT DISORDER is the #1 most commonly reported adverse reaction for ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY, manufactured by The Procter & Gamble Manufacturing Company. There are 4 FDA adverse event reports linking ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY to MOVEMENT DISORDER. This represents approximately 8.9% of all 45 adverse event reports for this drug.
Patients taking ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY who experience movement disorder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MOVEMENT DISORDER is moderately reported among ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY users, representing a notable but not dominant share of adverse events.
In addition to movement disorder, the following adverse reactions have been reported for ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY:
The following drugs have also been linked to movement disorder in FDA adverse event reports:
MOVEMENT DISORDER has been reported as an adverse event in 4 FDA reports for ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY. This does not prove causation, but indicates an association observed in post-market surveillance data.
MOVEMENT DISORDER accounts for approximately 8.9% of all adverse event reports for ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY, making it one of the most commonly reported side effect.
If you experience movement disorder while taking ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.